Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis

Treatment against visceral leishmaniasis (VL) is mainly hampered by drug toxicity, long treatment regimens and/or high costs. Thus, the identification of novel and low-cost antileishmanial agents is urgent. Acarbose (ACA) is a specific inhibitor of glucosidase-like proteins, which has been used for...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Rafaella R., Oliveira-da-Silva, João A., Reis, Thiago A. R., Tavares, Grasiele S. V., Mendonça, Débora V. C., Freitas, Camila S., Lage, Daniela P., Martins, Vívian T., Antinarelli, Luciana M. R., Machado, Amanda S., Bandeira, Raquel S., Ludolf, Fernanda, Santos, Thaís T. O., Brito, Rory C. F., Humbert, Maria V., Menezes-Souza, Daniel, Duarte, Mariana C., Chávez-Fumagalli, Miguel A., Roatt, Bruno M., Coimbra, Elaine S., Coelho, Eduardo A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053370/
https://www.ncbi.nlm.nih.gov/pubmed/33870453
http://dx.doi.org/10.1007/s00430-021-00707-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053370/
https://www.ncbi.nlm.nih.gov/pubmed/33870453
http://dx.doi.org/10.1007/s00430-021-00707-4

Ejemplares similares